other material
confidence medium
sentiment positive
materiality 0.75
Vaccinex presents neoadjuvant pepinemab combo data at ESMO; triple therapy shows 62.5% pCR in Stage III melanoma
VACCINEX, INC.
- Triple combination (nivolumab/ipilimumab/pepinemab) achieved 62.5% pathologic complete response (pCR) and 75% major pathologic response.
- Doublet pepinemab/nivolumab showed 25% pCR; pepinemab/ipilimumab 12.5% pCR; nivolumab alone 28.5% pCR.
- Triple combination demonstrated significantly improved recurrence-free survival vs doublets (logrank p=0.0097).
- All patients underwent surgery without delay; Grade 3 AEs were manageable (5/8 in triple arm).
- Correlative biomarker data to be presented at 2022 SITC; further studies needed to confirm durability.